LenioBio Partners with AffinityAI to Enhance Protein Discovery Using AI-Driven Approaches

LenioBio and AffinityAI: A Strategic Collaboration

In a groundbreaking move, LenioBio GmbH has announced a strategic partnership with the Danish startup AffinityAI, specializing in AI-powered protein design. This collaboration aims to significantly accelerate the discovery and optimization of de novo proteins, leveraging the strengths of both companies’ innovative technologies.

LenioBio is well-known for its proprietary cell-free protein expression platform, ALiCE®, which facilitates rapid protein production without the limitations posed by living cells. Meanwhile, AffinityAI, with its advanced design engine named Designerbodies™, excels at creating high-affinity proteins that are specifically engineered to bind to target epitopes. Together, these pioneering technologies form a powerful alliance that promises to transform protein discovery and development in the biotechnology landscape.

Accelerating Protein Discovery

One of the most exciting aspects of this partnership is the integration of AI-driven protein design with high-throughput cell-free expression. By combining these methodologies, LenioBio and AffinityAI aim to bridge the traditional gap between laboratory research and production. This collaboration is set to reduce the design, testing, and feedback cycles from weeks to just days, paving the way for a new era in protein engineering.

The pipeline developed through this partnership enables rapid generation and refinement of new protein sequences, which can then be swiftly expressed with LenioBio's ALiCE® platform. This synergy allows for quick screening and iterative optimization, even for the most challenging protein constructs. André Goerke, CEO of LenioBio, expressed his enthusiasm about the collaboration, stating, "We have reinvented cell-free protein expression to fully harness the potential of AI-driven protein design. ALiCE® combines the openness and flexibility of a cell-free system with the scalability typical of cell-based platforms. Together with AffinityAI, we can expedite research cycles, delivering precisely engineered protein therapeutics much faster."

The Role of Designerbodies™

AffinityAI specializes in a unique class of proteins known as Designerbodies™, which are synthetic and designed to offer enhanced binding capabilities compared to traditional antibodies. Unlike conventional methods that often take considerable time to develop suitable antibodies, Designerbodies™ are constructed with predefined binding sites, offering exceptional precision and control. Leveraging ALiCE® enables rapid evaluation and optimization of these designs, resulting in a high-throughput automated pipeline for next-generation protein products. Timothy P. Jenkins, Ph.D., CEO of AffinityAI, stated, "LenioBio’s ALiCE® system perfectly complements our AI-based approach. Together, we can deliver Designerbodies™ faster and with greater precision than ever before."

A Significant Step Forward

This partnership marks a significant step forward in the field of protein therapeutics, enhancing the speed and efficiency of developing novel treatments. By merging the best of AI technology with scalable cell-free expression capabilities, LenioBio and AffinityAI are set to lead the way in producing innovative protein-based solutions for drug development, diagnostics, and biomedical research.

About LenioBio

Founded in 2016 and headquartered in Düsseldorf, Germany, LenioBio GmbH is a pioneering biotechnology company focusing on cell-free protein expressions through its ALiCE® platform. The company is actively involved in fast-tracking the discovery, development, and scalable production of proteins beyond the constraints of living cells. More information can be found at www.leniobio.com or by following LenioBio on LinkedIn.

About AffinityAI

AffinityAI is a Copenhagen-based biotechnology firm that specializes in AI-driven protein design, focusing on its proprietary Designerbodies™. These fully synthetic small proteins are designed for specific binding to target proteins and are developed significantly faster than traditional antibodies, making them highly valuable in various applications such as drug development, diagnostics, and biomedical research. Find more at affinityai.dk.